TY - JOUR
T1 - Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis
AU - Hogan, Jonathan
AU - Avasare, Rupali
AU - Radhakrishnan, Jai
N1 - Publisher Copyright:
© 2014 by the American Society of Nephrology.
PY - 2014
Y1 - 2014
N2 - Clinical outcomes in ANCA-associated vasculitis (AAV) and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events,most notably infections, cytopenias,malignancies, and reproductive abnormalities. Multiple recent randomized controlled trials in AAV and lupus nephritis have compared cyclophosphamide-based regimenswith agents such as rituximab, mycophenolate mofetil, and azathioprine, with the hope of providing better clinical outcomes with improved safety profiles. Although some of these newer regimens are now considered first-line treatments of these diseases, their adverse event profiles have been disappointingly similar to those of cyclophosphamide-based protocols. Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, aswell as available measures to prevent such events, when choosing the ideal regimen for an individual patient.
AB - Clinical outcomes in ANCA-associated vasculitis (AAV) and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events,most notably infections, cytopenias,malignancies, and reproductive abnormalities. Multiple recent randomized controlled trials in AAV and lupus nephritis have compared cyclophosphamide-based regimenswith agents such as rituximab, mycophenolate mofetil, and azathioprine, with the hope of providing better clinical outcomes with improved safety profiles. Although some of these newer regimens are now considered first-line treatments of these diseases, their adverse event profiles have been disappointingly similar to those of cyclophosphamide-based protocols. Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, aswell as available measures to prevent such events, when choosing the ideal regimen for an individual patient.
UR - http://www.scopus.com/inward/record.url?scp=84908588638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908588638&partnerID=8YFLogxK
U2 - 10.2215/CJN.01600214
DO - 10.2215/CJN.01600214
M3 - Article
C2 - 24832093
AN - SCOPUS:84908588638
SN - 1555-9041
VL - 9
SP - 1657
EP - 1667
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 9
ER -